Gute Nachrichten...

Serious Black, Mittwoch, 24. November 2021, 10:33 (vor 1094 Tagen)

... aus Tübingen:

The CoVac-1 jab, which is being developed at the University of Tubingen in Germany, has successfully undergone its first human trial.

Both antibodies and the T-cells are factors in the body's immune response to a virus.

The body's immediate response is driven by antibodies, while the T-cells take longer to react but respond for longer and are key to longer-lasting protection.

This is because while antibody levels fall over time, T-cells can remain in the bloodstream for a number of years.

The CoVac-1 jab was shown to produce a strong T-cell response in all 36 of its Phase 1 trial participants.
The researchers also said the T-cell response was unaffected by current new variants.

They added: "Together, CoVac-1 showed a favourable safety profile and induced broad, potent and VOC-independent T- cell responses, supporting the presently ongoing evaluation in a phase II trial for patients with B cell/antibody deficiency."

https://www.lbc.co.uk/news/t-cell-covid-vaccine-germany-better-immune-response/